🇺🇸 FDA
Pipeline program

CD19X CAR-T

IIT2025136

Phase 2 small_molecule active

Quick answer

CD19X CAR-T for Large B-Cell Lymphoma (LBCL) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Large B-Cell Lymphoma (LBCL)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials